Diabetes Drug Halts Liver Scarring?

A medication widely used for diabetes and obesity, semaglutide, has demonstrated potential in reducing liver scarring associated with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease. Research from UC San Diego School of Medicine indicates that semaglutide, a GLP-1 receptor agonist, may offer a new therapeutic avenue for patients with advanced MASH, including those in early stages of cirrhosis.

The findings, published in The Lancet Gastroenterology & Hepatology on July 15, 2026, stem from a Phase II clinical trial involving approximately 700 adults. While a combination therapy with zalfermin did not outperform a placebo, semaglutide alone was shown to significantly improve liver scarring without exacerbating inflammation. This marks a notable development, as effective treatments for advanced MASH have historically been limited.

Researchers also observed that non-invasive monitoring methods, such as blood tests and imaging techniques, showed promising results in reflecting treatment-related improvements. This could potentially shift future patient monitoring away from invasive liver biopsies, making the process less burdensome and more repeatable.

Experts caution that while encouraging, these results are preliminary. Larger trials are needed to confirm semaglutide's efficacy, particularly in patients with cirrhosis. Lifestyle modifications like weight loss and improved blood sugar control remain crucial alongside medical supervision, with semaglutide intended to complement these measures rather than replace them.